Mobile Instrumentation for the Detection and Sampling of Aerosol Particles
Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring
Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters
New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins
Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach
This technology includes a novel advancement in developing vaccines targeting norovirus, tailored specifically for a more robust and effective response. It centers around an improved version of Virus-Like Particles (VLPs) uniquely engineered for greater stability and efficacy. These enhanced VLPs are designed to remain intact even when faced with the body's immune responses, overcoming a key limitation of previous vaccine designs.
Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response
The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant virus strains insensitive to treatment and with toxic effects following long-term usage.
Bacteriophage Based-Vaccine System
Vaccines have become one of the most important tools in the fight against cancers and infectious diseases. However, some vaccines have shown limitations due to their high cost and low immune responses. To overcome these limitations, bacteriophages were proposed for the development of more cost-effective, immunogenic vaccines. Phages have shown a strong ability to activate induced and adaptive immune systems. The genome of these viral particles can be engineered, and their surface proteins can be exploited for antigen display.
Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection
The Corona virus disease, 2019 (COVID-19) pandemic is a worldwide public health crisis with over 153 million confirmed cases and 3.2 million deaths as of April 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein, which has two portions, S1 that binds the cell and S2 that is involved in viral entry via fusion with the cell membrane. There are several vaccines available for COVID-19 patients that directly target SARS-CoV-2 by systemic immunization.